Can anyone take the top spot away from Eli Lilly in the anti-obesity area?

Continue » Eli Lilly's tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight management, is a direct competitor to Novo Nordisk's semaglutide, known under the brand names Ozempic and Wegovy.

Shares of Eli Lilly plummeted 14% on Thursday, pacing what would be the stock’s largest loss in decades after the pharmaceutical giant unveiled data for its obesity treatment pill that fell behind Wall Street’s expectations. Shares of rival Novo ...

It's not much of a rivalry yet.

Horror director Eli Roth has recently come under fire for using AI in the making of his latest film, Ice Cream Man. His open embrace of the technology has sparked a heated response, proving audiences are still hungry for human-made movies that continue the legacy of classic cinema.

Eli Lilly (LLY) stock jumps as the firm posts better-than-expected Q2 2026 results, driven by its injectable GLP-1s and its weight-loss pill, Foundayo. Read more here.

One of its more popular products just got the green light from a major national regulator.

Eli Lilly (NYSE:LLY) news: stronger than expected quarterly results, raised full-year guidance, and expanded Indiana manufacturing capacity for key therapies.